Peregrine Pharmaceuticals Inc. (PPHM)

2.48
0.01 0.40
NASDAQ : Health Technology
Prev Close 2.47
Open 2.46
Day Low/High 2.39 / 2.50
52 Wk Low/High 2.24 / 5.78
Volume 345.12K
Avg Volume 211.30K
Exchange NASDAQ
Shares Outstanding 45.21M
Market Cap 185.60M
EPS -0.90
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Avid Bioservices Announces Appointment Of Tracy Kinjerski As Vice President Of Business Operations

Avid Bioservices Announces Appointment Of Tracy Kinjerski As Vice President Of Business Operations

Senior Executive with Significant Business Development Experience at Leading Contract Development and Manufacturing Organizations (CDMOs)

Peregrine Pharmaceuticals, Ronin Trading And SW Investment Management Announce Settlement Agreement

Peregrine Pharmaceuticals, Ronin Trading And SW Investment Management Announce Settlement Agreement

Peregrine Board Reconstituted with Four New Independent Directors

Ronin Trading And SW Investment Management Release Presentation Highlighting Concerns With Board Of Peregrine Pharmaceuticals

Ronin Trading And SW Investment Management Release Presentation Highlighting Concerns With Board Of Peregrine Pharmaceuticals

Ronin Believes Recent Changes are Insufficient and Calls on Peregrine to Justify Long-Standing Incumbent Directors' Continued Service on the Board

Ronin Trading And SW Investment Management Announce Additional Nominations To Board Of Peregrine Pharmaceuticals

Ronin Trading And SW Investment Management Announce Additional Nominations To Board Of Peregrine Pharmaceuticals

CDMO Executive Richard (Rick) B. Hancock and Life Sciences Executive Joel McComb Join Slate of Six Highly Qualified Candidates for Election at Upcoming 2017 Annual Meeting

Peregrine Pharmaceuticals Announces Appointment Of Patrick Walsh To Board Of Directors Of Peregrine And Avid Bioservices

Peregrine Pharmaceuticals Announces Appointment Of Patrick Walsh To Board Of Directors Of Peregrine And Avid Bioservices

Industry Veteran with More Than Thirty Years of Experience Leading Successful Contract Development and Pharmaceutical Manufacturing Organizations

Peregrine Pharmaceuticals Announces Appointment Of Mark R. Bamforth To Board Of Directors Of Peregrine And Avid Bioservices

Peregrine Pharmaceuticals Announces Appointment Of Mark R. Bamforth To Board Of Directors Of Peregrine And Avid Bioservices

Senior Executive with Thirty Years of Biologics Experience including Contract Development and Manufacturing Organization (CDMO) Leadership

Peregrine Pharmaceuticals Series E Convertible Preferred Stock Shares Cross 11.5% Yield Mark

Peregrine Pharmaceuticals Series E Convertible Preferred Stock Shares Cross 11.5% Yield Mark

In trading on Monday, shares of Peregrine Pharmaceuticals Inc's 10.50% Series E Convertible Preferred Stock were yielding above the 11.5% mark based on its quarterly dividend (annualized to $2.625), with shares changing hands as low as $22.62 on the day. As of last close, PPHMP was trading at a 8.48% discount to its liquidation preference amount.

Ronin Trading And SW Investment Management Announce Additional Nomination To Board Of Peregrine Pharmaceuticals

Ronin Trading And SW Investment Management Announce Additional Nomination To Board Of Peregrine Pharmaceuticals

Biotech Industry Veteran James (Jamie) J. Egan Joins Slate of Four Highly Qualified Candidates for Election at Upcoming 2017 Annual Meeting

Stock Futures Rise as Irma Weakens to Tropical Storm and North Korea Is Quiet

Stock Futures Rise as Irma Weakens to Tropical Storm and North Korea Is Quiet

Stock futures are rising confidently.

Peregrine Pharmaceuticals Announces Appointment Of Roger J. Lias, Ph.D. As President Of Avid Bioservices

Peregrine Pharmaceuticals Announces Appointment Of Roger J. Lias, Ph.D. As President Of Avid Bioservices

Senior Executive with More Than Two Decades of CDMO Management Experience to Also Join Peregrine's Board of Directors

Peregrine Pharmaceuticals Announces First Patient Dosed In Phase II Clinical Trial Evaluating Bavituximab Treatment Combination In Patients With Newly Diagnosed Glioblastoma

Peregrine Pharmaceuticals Announces First Patient Dosed In Phase II Clinical Trial Evaluating Bavituximab Treatment Combination In Patients With Newly Diagnosed Glioblastoma

Trial is First of Three Planned Bavituximab Combination Studies Being Conducted as Part of Collaboration with National Comprehensive Cancer Network® (NCCN®)

Ronin Trading And SW Investment Management Respond To Recent Announcements By Peregrine Pharmaceuticals

Ronin Trading And SW Investment Management Respond To Recent Announcements By Peregrine Pharmaceuticals

Believe Incumbent Board Members are Responsible for Continued Destruction of Stockholder Value and Must be Held Accountable

Peregrine Provides Strategic Update

Peregrine Provides Strategic Update

Ronin Trading And SW Investment Management Issue Letter To Employees Of Peregrine Pharmaceuticals

Ronin Trading And SW Investment Management Issue Letter To Employees Of Peregrine Pharmaceuticals

Elaborate on Strategic Vision and Intentions with Respect to Peregrine

Peregrine Pharmaceuticals' Series E Preferred Stock Shares Cross 12% Yield Mark

In trading on Monday, shares of Peregrine Pharmaceuticals Inc's 10.50% Series E Convertible Preferred Stock were yielding above the 12% mark based on its quarterly dividend (annualized to $2.625), with shares changing hands as low as $21.11 on the day. This compares to an average yield of 10.68% in the "Biotechnology" preferred stock category, according to Preferred Stock Channel.